REVIEW PAPER
Nephrogenic systemic fibrosis
Online publication date: 2009-04-01
Reumatologia 2009;47(1):34-38
KEYWORDS
ABSTRACT
Development of new diagnostic and therapeutic technics makes possible to keep many patients alive. At the same time it carries risk of development of diseases which have not been observed in human pathology until now. Nephrogenic systemic fibrosis (NSF) is one of these diseases which is resembling systemic sclerodermia and characterized of skin and internal organs fibrosis. Without treatment this illness leads to the patients death. Patients who developed NSF were in advanced stages of chronic kidney disease. The relationship between exposure to gadolinium containing contrast agents and the appearance NSF symptoms was proved. Early diagnosis and prophylactic measures may prevent development of this disease. It is very important to inform physicians about this problem.
REFERENCES (37)
1.
Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kid Dis 2005; 46: 763-765.
2.
Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179-3185.
3.
Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
4.
Marckman P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Rad 2008; 66: 187-190.
5.
Nortier JL, del Marmol V. Nephrogenic systemic fibrosis – the need for a multidisciplinary approach. Nephrol Dial Transplant 2007; 22: 3097-3101.
6.
Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008; 9: 161-168.
7.
Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis predict early mortality and are associated with gadolinium exposure. Arthritis Rheum 2007; 56: 3433-3441.
8.
Kay J. What causes nephrogenic systemic fibrosis? Dialysis Transplant 2008; 3: 95-98.
9.
Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25: 358.
10.
Daram SR, Cortese CM, Bastani B. Nephrogenic Dermopathy/Nephrogenic Systemic Fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-759.
11.
Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-393.
12.
Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nefrogenic fibrosing dermopathy). Muscle Nerve 2004; 30: 569-577.
13.
Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130: 209-212.
14.
Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-906.
15.
Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Clin Pract Reumatol 2008; 4: 557-562.
16.
Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta-1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666.
17.
Marckman P, Skov L, Rossen K, et al. Case control study of gadodiamid-related nephrogenic systemic fibrosing. Nephrol Dial Transplant 2007; 22: 3174-3178.
18.
Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 2003; 15: 785-790.
19.
Swaminathan S, Ahmed J, McCarthy RC, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-235.
20.
Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21: 135-9.
21.
Mallo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6: 2212-2221.
22.
Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
23.
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
24.
Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examination the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-267.
25.
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
26.
Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJM Am J Roentgenol 2007; 188: 586-592.
27.
Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
28.
High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.
29.
Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008; 66: 160-167.
30.
Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Rad 2008; 66: 230-234.
31.
Morcos SK, Thompsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110: 24-32. .
32.
Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermathol 2003; 25: 204-209.
33.
Gilliet M, Cozzio A, Burg G, Nestle FO. Successfull treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531-536.
34.
Schmook T, Budde K, Urich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005; 20: 220-222.
35.
Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004; 140: 1401.
36.
Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high – dose intravenous immunoglobulin. Br J Dermatol 2004; 150: 596-597.
37.
Kay J. Imatinib mesylate treatment improves skin changes of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-2548.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
